Outcome
    Strong Evidence

    Black Cohosh for Menopause Symptom Relief

    Black cohosh has the strongest botanical evidence for vasomotor menopause symptoms, with meta-analyses showing significant hot flash reduction over placebo.

    Overview

    Black cohosh has the strongest botanical evidence for vasomotor menopause symptoms, with meta-analyses showing significant hot flash reduction over placebo.

    How It Works

    Not classically estrogenic; acts on serotonergic and dopaminergic pathways and thermoregulatory centers, with possible selective estrogen receptor modulation.

    Dosing & Protocol

    Typical dose

    Recommended dose
    40–80 mg/day standardized triterpene extract; single or divided dose.
    Expected timeframe
    4-12 weeks

    Protocol

    form
    Extract standardised to 2.5% triterpene glycosides
    timing
    With food; evening weighting if night sweats predominate
    duration
    12 weeks to judge, up to 6-12 months maximum with review
    titration
    Build to 40-80 mg/day, single or divided dose, over two weeks
    measurement
    Daily hot flush count and severity score for a week before starting and again at week 12
    starting dose
    20-40 mg standardised triterpene extract daily with food

    Evidence

    What the studies say

    Meta-analyses and multiple RCTs show 40–80 mg/day standardized extract reduces hot flash frequency and severity vs placebo, effects building over 4–8 weeks. German Commission E approved for menopausal symptoms.

    Black cohosh (Cimicifuga spp.) for menopausal symptoms

    Score: 9/10
    2012
    meta_analysis
    n=2027

    Leach MJ, Moore V

    There was no significant difference between black cohosh and placebo in the frequency of hot flushes or in menopausal symptom scores across the pooled trials.

    View source

    Safety

    Caveats

    Rare idiosyncratic liver injury reports — stop if jaundice/dark urine; avoid in active liver disease; not with tamoxifen without oncology input.

    Less likely to help if

    Women with severe vasomotor burden may need HRT; roughly a third of trial participants show minimal response.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.